Lexicon's Upcoming Virtual Webcast on Neuropathic Pain
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) is making waves in the biopharmaceutical industry with its upcoming virtual event titled "LX9211 - Changing the Paradigm for Treatment of Neuropathic Pain." Scheduled for January 28, 2025, from 9:00 a.m. to 11:00 a.m. ET, this event promises to deliver valuable insights into the ongoing developments surrounding LX9211, particularly its application in diabetic peripheral neuropathic pain.
Overview of LX9211 and Its Significance
As a company dedicated to pioneering transformative medicines, Lexicon aims to shed light on the innovative research that supports the use of LX9211. This virtual event will coincide with an anticipated update from the Phase 2b PROGRESS trial, providing essential data that could elevate existing treatment paradigms for patients suffering from diabetic peripheral neuropathic pain (DPNP).
Leadership Presentations
A highlight of the webinar will be the presentations from Lexicon's leadership team, including:
- Mike Exton, PhD, the Chief Executive Officer and Director of Lexicon Pharmaceuticals.
- Suma Gopinathan, PhD, who serves as the Vice President of Clinical Development.
- Craig Granowitz, MD, PhD, the Senior Vice President and Chief Medical Officer.
Expert Panel Discussions
Alongside leadership presentations, the event will feature an expert panel exploring the complexities of DPNP. This segment will include esteemed professionals such as:
- Rodica Pop-Busui, MD, PhD, who chairs the Jordan Schnitzer Chair in Diabetes at the Oregon Health & Science University.
- Steve Edelman, MD, a prominent figure in diabetes education and research from the University of California San Diego.
These discussions promise to deepen the audience's understanding of diabetic neuropathic pain and the potential role of LX9211 in treatment.
Registering for the Event
Interested participants should register for this enlightening experience, available in the “Events” section of the Lexicon website. Following the event, a recording will be accessible, ensuring that even those unable to attend live can catch up on the fundamental discussions and findings presented.
About Lexicon Pharmaceuticals
Founded with a mission to innovate healthcare, Lexicon Pharmaceuticals is a biopharmaceutical company focused on discovering and developing breakthrough medicines. Through their Genome5000™ initiative, Lexicon explores gene functionalities, identifying essential protein targets that hold therapeutic promise across various medical conditions. Their ongoing work encompasses an impressive pipeline of drug candidates aimed at treating several indications, including neuropathic pain, cardiology, and metabolic diseases.
Contact Information
For inquiries concerning investor relations or media, you can reach out to:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
Frequently Asked Questions
What is the purpose of the virtual webcast hosted by Lexicon?
The webcast intends to provide insights into LX9211 and its impact on treating diabetic peripheral neuropathic pain.
Who are the speakers during the Lexicon webcast?
Key speakers include Mike Exton, Suma Gopinathan, and Craig Granowitz, alongside notable experts in the field.
How can I register for the Lexicon webcast?
Registration is available on Lexicon's official website under the “Events” section.
What is LX9211 being evaluated for?
LX9211 is being evaluated as a treatment option for diabetic peripheral neuropathic pain.
Where can I find more information about Lexicon Pharmaceuticals?
More information can be found on Lexicon's website, detailing their mission, research, and developments in drug innovation.
